Michael is CEO and Co-Founder of Leukocare, heading strategy, finance, corporate law, marketing & sales and HR. Before joining Leukocare, Michael was an entrepreneur and investor and founded several technology companies. He started his career as business consultant at BCG. Michael holds a master’s degree in business engineering from the University of Berlin.
Dr. Georg Dönges
Georg has spent more than 10 years in leading positions in the biotech industry & capital markets. He held various positions in a large finance org., eg. lead for restructuring of Corp. Finance at GfK SE, a KKR portfolio company. Previously, Georg worked at the Max-Planck-Institute of Biochemistry for his PhD thesis and earned the degree of a Certified International Investment Analyst (CIIA).
Dr. Cornelius Pompe
Chief Development Officer (CDO)
Cornelius brings more than 15 years of experience in early and late stage biopharmaceutical development. Before joining Leukocare, Cornelius served as Drug Product Development Head, Early Operations Lead and Member of the Process Development Senior Leadership Team at Amgen Research Munich/Micromet. Prior to his roles at Amgen/Micromet, he held several roles in the area of drug product development such as Head of Freeze-Dried Drug Product Development Unit at LFB (France) and Head of Formulation Development and Project Coordination at Coriolis. Cornelius holds a PhD in Pharmaceutical Technology from Ludwig Maximilians University Munich.
Dr. Dirk Winnemöller
Chief Business Officer (CBO)
Dirk brings more than 14 years of experience in business operations and international marketing and sales in the biotechnology as well as biopharma industries to Leukocare. Before joining Leukocare, Dirk served as Global Vice President Business Development, Alliances and Organizational Strategy at Miltenyi Biomedicine GmbH. He was responsible for Business Development, Alliances/Partnering, Project Management, Communications, Organizational Strategy and Supply Chain. Prior to this role, Dirk held several commercial leadership positions including country manager DACH and Australia for Miltenyi Biotec. He holds a Dr. rer.nat from the Institute of Reconstructive Neurobiology, University of Bonn.
Dr. Sabine Hauck
Executive Vice President, Corporate Development
Sabine brings 20 years of Drug Product development expertise as well as several years of in vitro diagnostic and biosensor development to Leukocare. Before joining Leukocare, Sabine was heading Pharmaceutical Development, QA and RA departments (Medigene, Acino, IDEA). She holds a Dr. rer. nat. from University of Regensburg.
Dr. Andreas Geissler
Executive Vice President, IP and Legal
Andreas has been counseling pharmaceutical biotech companies on IP strategy for more than 15 years. He is a European and German Patent Attorney. Before joining Leukocare, Andreas served as Head of IP (Medigene) and attorney in private practice. He has in depth experience in IP strategy, portfolio management, patent prosecution, and FTO analysis. He holds a PhD in Molecular Cell Biology from Albert-Ludwigs-University Freiburg.